[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649216":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":25,"centralContacts":26,"locations":36,"responsibleParty":59,"collaborators":25,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":25,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":25,"enrollmentInfo":71,"targetDuration":25,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":84,"overallStatus":87,"whyStopped":25,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Unity Health Toronto","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants seeking HIV and STBBI testing","EXPERIMENTAL","Participants will screen with Health Canada approved rapid antibody tests for HIV, syphillis and\u002For HCV. Screen results may impact which GeneXpert test that participants can receive.",[13],"Device: Xpert® HIV-1 Qual XC",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Xpert® HIV-1 Qual XC","Xpert® HIV-1 Qual XC: Xpert HIV-1 Qual XC (extended coverage) is an in vitro nucleic acid amplification test for the qualitative detection of HIV-1 total nucleic acids, on the automated GeneXpert® system. Xpert HIV-1 Qual XC is intended to aid in the diagnosis of HIV-1 infection in conjunction with clinical presentation and other point-of-care and laboratory markers in infant, adolescent, and adult populations. It is a molecular point-of-care test that delivers actionable results in around 90 minutes. The HIV-1 Qual XC assay uses reverse transcription polymerase chain reaction (RT-PCR) technology to achieve high sensitivity for the qualitative detection of HIV-1 total nucleic acids in WB or DBS specimen types.",[9],[21,22,23,24],"Xpert® HIV-1 VL XC","Xpert® CT\u002FNG","Xpert® HCV VL Fingerstick","Xpert® HPV",null,[27,32],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},"Sean B Rourke","CONTACT","416-878-2779","Sean.Rourke@unityhealth.to",{"name":33,"role":29,"phone":34,"phoneExt":25,"email":35},"Megan Cedrone","(647)-786-8711","Megan.Cedrone@unityhealth.to",[37,49],{"facility":38,"status":25,"city":39,"state":40,"zip":25,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":25},"Anishnawbe Health Toronto","Toronto","Ontario","Canada","CA",{"type":44,"coordinates":45},"Point",[46,47],-79.39864,43.70643,{"lat":47,"lon":46},{"facility":50,"status":25,"city":39,"state":40,"zip":25,"country":41,"countryCode":42,"cosmosGeoPoint":51,"geoPoint":53,"contacts":54},"Women's Health In Women's Hands Community Health Centre",{"type":44,"coordinates":52},[46,47],{"lat":47,"lon":46},[55],{"name":56,"role":29,"phone":57,"phoneExt":25,"email":58},"Wangari Tharao","(416) 593-7655","wangari@whiwh.com",{"type":60,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100649216","national-rapid-tlc-testing-and-linkage-to-care-100649216",false,"NCT07730801","National Rapid TLC: Testing and Linkage to Care","Rapid Testing and Linkage to Care for Underserved and Undiagnosed Populations at Risk of HIV and STBBIs or Living With HIV and STBBIs Across Canada Using the GeneXpert System","Inclusion Criteria:\n\n* Individuals accessing STBBI testing at specific locations who are ≥ 16 years of age\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Unable to provide signed informed consent (e.g., intoxicated)\n* In the opinion of the site PI \u002Fstudy operator, the participant is unable to complete the study elements.\n* Participants who have previously enrolled in the study.",true,"ALL","16 Years",{"count":72,"type":73},2500,"ESTIMATED","INTERVENTIONAL",[76],"NA","The goal of this cross-sectional study is to learn if the GeneXpert system is a practical system for HIV and STBBI testing in community-based organizations and health clinics. The study involves a clinical trial to learn if the HIV-1 Qual XC test works to identify HIV in near-patient settings. The main questions it aims to answer are to create a near-patient testing model for testing and treating patients in a single visit, and to learn if the HIV-1 Qual XC test works to accurately detect HIV in patients. Patients who come to study sites to ask for HIV or STBBI testing will be given the option to participate in the study. Those who agree with provide samples for the tests of their choice and answer survey questions before and after their tests are completed. Those who participate in the clinical trial will have a blood sample sent to provincial labs to compare the results to the HIV -1 Qual XC test. Follow-up visits will be done at 1,3 and 6 months to see if patients completed treatment and\u002For remained connected to care.",[79,80,81,82,83],"HIV","Chlamydia","Gonorrhea","HCV","HPV",[85,41,86],"device trial","GeneXpert","NOT_YET_RECRUITING","2026-07-27",{"date":90,"type":91},"2026-07-28","ACTUAL",{"date":93,"type":73},"2026-08-01",{"date":95,"type":73},"2028-03",{"name":5,"class":6},2]